AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Community Health Needs Assessment in Janakpurdham Sub-Metropolitan City, Madhesh Province, Nepal
By Dr. Binay Shah
Janakpurdham Sub-Metropolitan City is the capital of Nepal's Madhesh Province, which shares a southern border with India.
Community Health Needs Assessment in Janakpurdham Sub-Metropolitan City, Madhesh Province, Nepal
By Dr. Binay Shah
Janakpurdham Sub-Metropolitan City is the capital of Nepal's Madhesh Province, which shares a southern border with India.
Community Health Needs Assessment in Janakpurdham Sub-Metropolitan City, Madhesh Province, Nepal
By Dr. Binay Shah
Janakpurdham Sub-Metropolitan City is the capital of Nepal's Madhesh Province, which shares a southern border with India.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed